NeurAxis Achieves Milestone with New CPT Code
NeurAxis, Inc. is making significant strides in the field of medical technology with its innovative solutions aimed at treating chronic and debilitating conditions. Recently, the American Medical Association (AMA) announced the establishment of a new Current Procedural Terminology (CPT) Category I code specifically for Percutaneous Electrical Nerve Field Stimulation (PENFS). This exciting development will be effective from January 1, 2026.
Understanding PENFS Technology
NeurAxis' flagship product, the IB-Stim, is a non-invasive device that has been cleared by the FDA to address functional abdominal pain linked to irritable bowel syndrome (IBS) in adolescents aged 11-18 years. This device administers gentle electrical impulses to specific cranial nerve bundles in the ear, providing a therapeutic effect for young patients suffering from abdominal pain-related disorders. Notably, there are currently no FDA-approved pharmacological treatments available for these issues in children, making IB-Stim a much-needed solution.
Statement from the Leadership
Brian Carrico, the President and Chief Executive Officer of NeurAxis, expressed his enthusiasm regarding the new CPT code, stating, "This is a wonderful day for children and adolescents suffering from IBS. The availability of a Category I code acknowledges the strong clinical evidence supporting PENFS procedures enabled by our IB-Stim technology. This milestone is crucial as we work to enhance patient awareness of FDA-cleared options and expand access to effective PENFS treatment strategies."
The Vision Behind NeurAxis
NeurAxis is committed to improving healthcare through the advancement of neuromodulation therapies. The company focuses on evidence-based strategies to encourage the adoption of its IB-Stim technology among medical professionals, scientific communities, and patients alike. The ongoing research and further clinical trials aim to explore the applicability of PENFS across a variety of pediatric and adult medical conditions, addressing significant unmet healthcare needs.
Layering Innovations
With numerous clinical trials currently underway, NeurAxis is dedicated to exploring the potential of PENFS technology in treating a range of clinical challenges. The landscape of medical treatments, especially targeted at pain management and neuromodulation, is evolving, and NeurAxis is at the forefront of this movement, working tirelessly to expand its therapeutic offerings.
Future Directions for NeurAxis
As the organization progresses, further innovation will be critical to maintaining its competitive edge in the medical technology sector. NeurAxis aims to continually update stakeholders by sharing information about advances in research and developments related to IB-Stim and other products in their pipeline. The next steps involve not only advocating for greater treatment accessibility but also providing comprehensive education on the benefits of PENFS for patients and healthcare providers.
Frequently Asked Questions
What is the significance of the new CPT code for PENFS?
The new CPT code allows for standardized billing and coding for Percutaneous Electrical Nerve Field Stimulation procedures, enhancing treatment access for patients.
Who can benefit from NeurAxis' IB-Stim technology?
Adolescents aged 11-18 years suffering from functional abdominal pain associated with IBS can benefit from IB-Stim technology, which offers a non-surgical solution.
What makes IB-Stim different from other treatments?
IB-Stim is unique as it offers a non-invasive alternative to pharmacological treatments, which can often lack efficacy and come with side effects.
How is NeurAxis contributing to the medical technology field?
NeurAxis is dedicated to advancing therapies that address chronic conditions, focusing on evidence-based medicine to promote the adoption of their innovative technologies.
What are the future plans for NeurAxis?
The company aims to continue its research and development for PENFS technology and expand its applications across other medical conditions requiring effective treatment solutions.
